On the morning of January 22, InnoMind Sensing (Yangxin) Medical Technology Co., Ltd. officially began trial production. As a high-tech enterprise focused on electrochemical biosensors and closed-loop glucose management, its commissioning not only expands the industrial footprint of InnoMind but also serves as a powerful driver for the innovation and upgrading of Yangxin County's medical industry.
It is reported that the project has a total investment of approximately 36 million RMB, features an international standard clean production line with an annual capacity exceeding 1 million units, and has built a strong technical moat with over 50 proprietary intellectual property rights. The company has achieved localization of core components through fully self-developed processes, significantly reducing production costs while maintaining strict quality control, making high-quality glucose monitoring products accessible to more ordinary consumers.
Lu Shilong, Director of InnoMind Sensing (Yangxin) Medical Technology Co., Ltd., explained that the glucose sensor is essentially a typical electrochemical sensor. Through innovative sensor formulations and industry-leading manufacturing process technologies, the company can effectively reduce costs to less than one-fourth of traditional levels. At the same time, through sensor process manufacturing, the yield rate can be greatly improved. The company's integrated design of the overall product device has greatly enhanced the user experience, and it hopes to bring the product to broader markets to benefit more diabetes patients.
Huang Xin, Chairman of InnoMind Sensing (Yangxin) Medical Technology Co., Ltd., stated that the company's products have a market of nearly one trillion RMB overseas, and the company's team has extensive overseas marketing experience, enabling active expansion into international markets. One of the reasons for choosing to establish operations in Yangxin is its large population and numerous vocational schools, which can fully meet the company's recruitment needs.
The commissioning of InnoMind Sensing injects new momentum into Yangxin County's medical device industry and will provide better, more accessible glucose management solutions for diabetes patients worldwide. The implementation of this project also demonstrates Yangxin's appeal to tech innovation enterprises, and more high-quality projects are expected to gather here in the future.
Zhong Guijiang, Partner of Wuhan Hanyang Investment Development Group, said that the company has established a joint fund with Yangxin to enable R&D in Wuhan and production in Yangxin. In the past two years, five or six enterprises have already settled in Yangxin, and he looks forward to deeper cooperation with Yangxin in the future to promote more industry clustering and growth in Yangxin.
Moving forward, Yangxin County will continue to optimize its business environment, leverage industrial funds and resource advantages, promote the cluster development of the medical device industry, and help more domestic tech innovation enterprises take root, grow, and reach the global stage.
